A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
Astrazeneca’s goal of bringing the second new lupus drug in over half a century to the market is a step closer, but all hangs on the FDA accepting mixed clinical data.
A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.